目的 探討欖香烯注射液聯(lián)合曲妥珠單抗治療局部晚期乳腺癌的臨床療效。方法 選取2016年2月-2017年5月在海南醫(yī)學(xué)院第一附屬醫(yī)院治療的局部晚期乳腺癌患者72例，隨機(jī)將患者分為對(duì)照組（36例）和治療組（36例）。對(duì)照組靜脈滴注注射用曲妥珠單抗，首劑量8 mg/kg加入500 mL生理鹽水，維持劑量6 mg/kg，1次/21 d。治療組在對(duì)照組基礎(chǔ)上經(jīng)股動(dòng)脈穿刺注入欖香烯注射液，100 mL/次，1次/7 d。3周為1個(gè)療程，兩組均治療4個(gè)療程。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者QLQ-C30評(píng)分和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組客觀緩解率為33.33%，疾病控制率為63.89%均分別顯著低于治療組的55.56%和83.33%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組QLQ-C30評(píng)分均明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組QLQ-C30評(píng)分顯著高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組CA125、CA153、腫瘤特異生長(zhǎng)因子（TSGF）水平均顯著降低，干擾素-γ（IFN-γ）和IL-2水平顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述血清學(xué)指標(biāo)治療后水平明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 欖香烯注射液聯(lián)合曲妥珠單抗治療局部晚期乳腺癌可有效改善機(jī)體細(xì)胞因子水平，利于改善患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Elemene Injection combined with trastuzumab in treatment of locally advanced breast cancer. Methods Patients (72 cases) with locally advanced breast cancer in the First Affiliated Hospital of Hainan Medical University from February 2016 to May 2017 were randomly divided into control (36 cases) and treatment (36 cases) groups. Patients in the control group were iv administered with Trastuzumab Injection, the first dose was 8 mg/kg, and it was added into normal saline 500 mL, and the maintenance dose was 6 mg/kg, once every 21 d. Patients in the treatment group were puncture injection administered with Elemene Injection via femoral artery on the basis of the control group, 100 mL/time, once every 7 d. 3 weeks as a course of treatment, and patients in two groups were treated for 4 courses of treatment. After treatment, the clinical efficacy was evaluated, and the QLQ-C30 scores and the serological indexes in two groups before and after treatment were compared. Results After treatment, the objective remission rate in the control group was 33.33%, and the disease control rate was 63.89%, which were significantly lower than 55.56% and 83.33% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the QLQ-C30 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the QLQ-C30 scores in the treatment group after treatment were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the CA125, CA153 and TSGF levels in two groups were significantly decreased, but IFN-γ and IL-2 levels were significantly increased, and there were differences in the same group (P<0.05). And the serological indexes in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Elemene Injection combined with trastuzumab in treatment of locally advanced breast cancer can effectively improve the cytokine level and the quality of life, which has a certain clinical application value.

海南省重點(diǎn)科技計(jì)劃項(xiàng)目（ZDYF2016107）